Xuan Xiaoyu, Fan Jilin, Zhang Jingyi, Ren Ming, Feng Limin
College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Department of Rehabilitation, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, China.
Front Immunol. 2025 May 8;16:1558484. doi: 10.3389/fimmu.2025.1558484. eCollection 2025.
Myocardial infarction (MI), which is characterized by high morbidity and mortality, is a serious threat to human life and health, and timely reperfusion therapy to save ischemic myocardium is currently the most effective intervention. Although reperfusion therapy effectively restores coronary blood flow and maximally limits the infarct size, it triggers additional cell death and tissue damage, which is known as myocardial ischemia/reperfusion injury (MIRI). Multiple immune cells are present in the reperfusion area, executing specific functions and engaging in crosstalk during diverse stages, constituting a complex immune microenvironment involved in tissue repair and regeneration after MIRI. Immunotherapy brings new hope for treating ischemic heart disease by modulating the immune microenvironment. In this paper, we explore the regulatory roles of various immune cells during MIRI and the close relationship between different cell deaths and the immune microenvironment. In addition, we present the current status of research on targeting the immune system to intervene in MIRI, with the expectation of providing a basis for achieving clinical translation.
心肌梗死(MI)发病率和死亡率高,严重威胁人类生命健康,及时进行再灌注治疗以挽救缺血心肌是目前最有效的干预措施。尽管再灌注治疗能有效恢复冠状动脉血流并最大程度限制梗死面积,但它会引发额外的细胞死亡和组织损伤,即心肌缺血/再灌注损伤(MIRI)。再灌注区域存在多种免疫细胞,它们在不同阶段执行特定功能并相互作用,构成了参与MIRI后组织修复和再生的复杂免疫微环境。免疫疗法通过调节免疫微环境为治疗缺血性心脏病带来了新希望。在本文中,我们探讨了各种免疫细胞在MIRI过程中的调节作用以及不同细胞死亡与免疫微环境之间的密切关系。此外,我们介绍了针对免疫系统干预MIRI的研究现状,期望为实现临床转化提供依据。